Morgan Stanley
ADAP

Morgan Stanley’s Adaptimmune Therapeutics ADAP Stock Holding History

Morgan Stanley’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,666,061
Closed -$477K – 8200
2025
Q3 		$477K Sell
3,666,061
-566,207
-13% -$77.7K ﹤0.01% 5512
2025
Q2 		$1.01M Buy
4,232,268
+1,516,321
+56% +$405K ﹤0.01% 5094
2025
Q1 		$535K Buy
2,715,947
+1,391,083
+105% +$720K ﹤0.01% 5296
2024
Q4 		$714K Sell
1,324,864
-374,161
-22% -$273K ﹤0.01% 5261
2024
Q3 		$1.61M Buy
1,699,025
+1,258,193
+285% +$1.43M ﹤0.01% 4771
2024
Q2 		$430K Buy
440,832
+67,551
+18% +$74.1K ﹤0.01% 5362
2024
Q1 		$590K Sell
373,281
-3,540,035
-90% -$4.27M ﹤0.01% 5235
2023
Q4 		$3.1M Buy
3,913,316
+1,861,970
+91% +$1.05M ﹤0.01% 4686
2023
Q3 		$1.6M Sell
2,051,346
-25,826
-1% -$21.7K ﹤0.01% 4524
2023
Q2 		$1.92M Sell
2,077,172
-175,252
-8% -$209K ﹤0.01% 4450
2023
Q1 		$2.46M Sell
2,252,424
-37,424
-2% -$58K ﹤0.01% 4327
2022
Q4 		$3.34M Buy
2,289,848
+22,082
+1% +$35.8K ﹤0.01% 4090
2022
Q3 		$2.44M Buy
2,267,766
+187,297
+9% +$344K ﹤0.01% 4285
2022
Q2 		$3.54M Buy
2,080,469
+27,034
+1% +$46.4K ﹤0.01% 4072
2022
Q1 		$4.23M Sell
2,053,435
-190,038
-8% -$513K ﹤0.01% 3860
2021
Q4 		$8.41M Buy
2,243,473
+1,908,502
+570% +$8.69M ﹤0.01% 3133
2021
Q3 		$1.73M Sell
334,971
-1,953,560
-85% -$8.76M ﹤0.01% 4677
2021
Q2 		$9.75M Sell
2,288,531
-2,435,031
-52% -$11.8M ﹤0.01% 3020
2021
Q1 		$25.1M Sell
4,723,562
-663,926
-12% -$3.8M ﹤0.01% 1707
2020
Q4 		$29M Buy
5,387,488
+5,092,210
+1,725% +$27.7M ﹤0.01% 1493
2020
Q3 		$2.36M Buy
295,278
+257,361
+679% +$2.25M ﹤0.01% 3512
2020
Q2 		$380K Buy
37,917
+9,272
+32% +$58.2K ﹤0.01% 4742
2020
Q1 		$77K Buy
28,645
+2,782
+11% +$9.23K ﹤0.01% 5296
2019
Q4 		$31K Sell
25,863
-377,598
-94% -$403K ﹤0.01% 5983
2019
Q3 		$609K Buy
403,461
+245,523
+155% +$574K ﹤0.01% 4597
2019
Q2 		$635K Sell
157,938
-78,849
-33% -$321K ﹤0.01% 4480
2019
Q1 		$1.02M Buy
236,787
+187,604
+381% +$874K ﹤0.01% 4100
2018
Q4 		$283K Buy
49,183
+40,913
+495% +$302K ﹤0.01% 5128
2018
Q3 		$112K Sell
8,270
-239,452
-97% -$2.51M ﹤0.01% 5652
2018
Q2 		$2.94M Buy
247,722
+90,964
+58% +$1.13M ﹤0.01% 3714
2018
Q1 		$1.76M Buy
156,758
+96,119
+159% +$841K ﹤0.01% 4120
2017
Q4 		$405K Buy
60,639
+29,515
+95% +$228K ﹤0.01% 5087
2017
Q3 		$254K Buy
31,124
+21,753
+232% +$136K ﹤0.01% 5233
2017
Q2 		$42K Buy
9,371
+698
+8% +$3.65K ﹤0.01% 5903
2017
Q1 		$48K Buy
+8,673
New +$37.9K ﹤0.01% 5842
2016
Q4 		– Sell
-3,570
Closed -$25K – 6515
2016
Q3 		$25K Sell
3,570
-4,624
-56% -$35.3K ﹤0.01% 5839
2016
Q2 		$67K Sell
8,194
-1,437
-15% -$13.5K ﹤0.01% 5418
2016
Q1 		$78K Buy
9,631
+4,443
+86% +$36.3K ﹤0.01% 5426
2015
Q4 		$62K Buy
5,188
+2,666
+106% +$26.1K ﹤0.01% 5629
2015
Q3 		$30K Sell
2,522
-8,995
-78% -$127K ﹤0.01% 5907
2015
Q2 		$211K Buy
+11,517
New +$198K ﹤0.01% 5204

Other funds holding ADAP

JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
EF
Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Morgan Stanley's ADAP Position: Q4 2025 in Review

Morgan Stanley sold out of Adaptimmune Therapeutics (ADAP) in Q4 2025, closing a stake of 3,666,061 shares — an estimated $477K sold.

Morgan Stanley first reported a position in ADAP in Q2 2015 and held it in 41 quarters. The position peaked at $29M in Q4 2020. 10 funds tracked by Wall St. Rank hold ADAP as of Q4 2025.

  • Morgan Stanley reported no remaining Adaptimmune Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Morgan Stanley sold 3,666,061 Adaptimmune Therapeutics shares in Q4 2025, an estimated $477K.
  • Morgan Stanley first reported a position in Adaptimmune Therapeutics in Q2 2015 and held it in 41 quarters.
  • Morgan Stanley's Adaptimmune Therapeutics position peaked at $29M in Q4 2020.
  • 10 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2025.

Based on Morgan Stanley's 13F filing for Q4 2025, filed 13 Feb 2026.